Serife BAYRAKTAR
Zafer CEBECI
Belgin IZGI
Kamber KASALI

Abstract The aim of this study was to examine the effect of the glaucoma medication on Choroidal Thickness (CT) in those with Primary Open-Angle Glaucoma (POAG) and normal cases. This prospective study included ۲۷ patients with newly diagnosed POAG (group ۱; ۴۹ eyes), undergoing glaucoma treatment, and ۳۰ patients, whose treatment was terminated due to misdiagnosis (group ۲; ۵۷ eyes). Choroidal thickness was measured using Enhanced Depth Imaging (EDI) with Spectral Domain Optical Coherence Tomography (SD-OCT) at the first visit and almost one month later. In group ۱, the mean Sub-Foveal CT (SFCT) was ۳۰۱ ± ۹۱ µm, the mean CT was ۲۶۴ ± ۸۷ µm at the nasal point, ۱ mm to the fovea, and ۲۷۱ ± ۸۴ µm at the temporal point, ۱ mm to the fovea. The second measurements were obtained as ۳۹ ± ۸.۵ days after treatment began; the SFCT was ۳۱۹ ± ۸۵ µm (P = ۰.۰۰۱۷), the nasal ۱ mm CT was ۲۷۵ ± ۸۸ µm (P = ۰.۱۶۲), and the temporal ۱mm CT was ۲۹۱ ± ۸۰ µm (P = ۰.۰۰۷). In group ۲, the mean SFCT was ۲۹۲ ± ۱۰۰ µm, the nasal ۱ mm CT was ۲۵۴ ± ۹۷ µm, and the temporal ۱ mm CT was ۲۶۱ ± ۹۷ µm. The second measurements were obtained ۳۷.۵ ± ۵.۵ days after the treatment ended; the SFCT was ۲۹۵ ± ۱۰۷ µm (P = ۰.۲۱۲), the nasal ۱ mm CT was ۲۶۲ ± ۱۰۴ µm (P = ۰.۷۰۹), and the temporal ۱ mm CT was ۲۶۶ ± ۱۰۴ µm (P = ۰.۷۹۲). Glaucoma medication affects the CT as a marker for choroidal blood flow in patients with glaucoma. Further studies with larger sample sizes are required to examine each glaucoma medication subgroup.